# Source Documents and References - GBM Clinical Data

## üèõÔ∏è OFFICIAL FDA DOCUMENTS

### Temozolomide (TEMODAR)
- **FDA NDA Number**: 021029
- **Current FDA Label (2023)**: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021029s036_037_038lbl.pdf
- **FDA Label (2020 Capsules)**: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/21029s035lbl.pdf
- **FDA Label (2016)**: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021029s031lbl.pdf
- **Drug Approval Package**: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21029_Temodar.cfm
- **DailyMed (Current)**: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819571ea-b808-4fd8-93c7-1ea2e33d71cf
- **DailyMed (Generic)**: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c1e05c21-a411-4493-80de-ede373632475

### Bevacizumab (AVASTIN)
- **FDA BLA Number**: 125085
- **Current FDA Label (2022)**: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125085s340lbl.pdf
- **FDA Label (2017)**: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125085s319lbl.pdf
- **FDA Label (2014)**: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s301lbl.pdf
- **Original GBM Approval (2009)**: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0169lbl.pdf
- **Drug Approval Package**: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/STN-125085_Avastin.cfm
- **DailyMed (Current)**: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e
- **FDA Safety Information**: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/avastin-bevacizumab-information

## üìã NCCN GUIDELINES

### Professional Guidelines
- **NCCN CNS Cancers (Version 2.2025)**: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425
- **Guidelines Summary**: Available to NCCN members
- **Evidence Blocks**: https://www.nccn.org/guidelines/guidelines-with-evidence-blocks

### Patient Guidelines
- **NCCN Guidelines for Patients - Brain Gliomas**: https://www.nccn.org/patients/guidelines/content/PDF/brain-gliomas-patient.pdf

## üî¨ PIVOTAL CLINICAL TRIALS

### Temozolomide FDA Approval Trials
- **EORTC 26981/22981 (Stupp Trial)**:
  - **Citation**: Stupp R, et al. N Engl J Med. 2005;352:987-996
  - **DOI**: 10.1056/NEJMoa043330
  - **PubMed ID**: 15758009
  - **Title**: "Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma"

### Bevacizumab FDA Approval Trials
- **AVF3708g (Single-arm trial)**:
  - **Citation**: Friedman HS, et al. J Clin Oncol. 2009;27:4733-4740
  - **PubMed ID**: 19720927
  - **Title**: "Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma"

- **RTOG 0825 (Phase III)**:
  - **Citation**: Gilbert MR, et al. N Engl J Med. 2014;370:699-708
  - **DOI**: 10.1056/NEJMoa1308573
  - **Title**: "A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma"

- **AVAglio Trial (Phase III)**:
  - **Citation**: Chinot OL, et al. N Engl J Med. 2014;370:709-722
  - **DOI**: 10.1056/NEJMoa1308345
  - **Title**: "Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma"

## üìä RECENT CLINICAL RESEARCH (2024)

### Extended TMZ Treatment Studies
- **Citation**: Spandidos Publications - Oncology Letters 2024
- **Title**: "Temozolomide based treatment in glioblastoma: 6 vs. 12 months"
- **DOI**: 10.3892/ol.2024.14551

### Bevacizumab Meta-Analysis (2024)
- **Citation**: Frontiers in Medicine, February 2024
- **Title**: "The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis"
- **DOI**: 10.3389/fmed.2024.1419038

## üè• HOSPITAL PROTOCOL SOURCES

### Major Cancer Centers
- **Mayo Clinic**: https://www.mayo.edu/research/clinical-trials/diseases-conditions/glioblastoma
- **MD Anderson**: https://www.mdanderson.org/cancer-types/glioblastoma.html
- **Cleveland Clinic**: https://my.clevelandclinic.org/services/gliomas-glioblastomas-treatment
- **Johns Hopkins**: https://www.hopkinsmedicine.org/health/conditions-and-diseases/glioblastoma-multiforme-gbm

### Quality Organizations
- **Commission on Cancer Standards**: https://www.facs.org/quality-programs/cancer/coc/
- **NCCN Outcomes Database**: https://www.nccn.org/about/news

## üìñ CLINICAL REFERENCE SOURCES

### Drug Information Databases
- **Medscape**: https://reference.medscape.com/drug/temodar-temozolomide-342229
- **Drugs.com**: https://www.drugs.com/dosage/temozolomide.html
- **Mayo Clinic Drug Information**: https://www.mayoclinic.org/drugs-supplements/temozolomide-oral-route/description/drg-20066228

### Professional Medical Literature
- **Clinical Cancer Research**: FDA approval summaries
- **Journal of Clinical Oncology**: Clinical trial reports
- **Journal of Neuro-Oncology**: Specialized research

## üåê MANUFACTURER RESOURCES

### Temozolomide (Merck/Schering-Plough)
- **Professional Website**: Available through medical portals
- **Prescribing Information**: Via DailyMed links above

### Bevacizumab (Genentech/Roche)
- **Avastin HCP Website**: https://www.avastin.com/hcp.html
- **rGBM Dosing Information**: https://www.avastin.com/hcp/rgbm/dosing-usage.html
- **Complete Prescribing Info**: Via DailyMed and FDA links above

## üìã REGULATORY AGENCIES

### US Food and Drug Administration
- **Drug Database**: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- **Safety Communications**: https://www.fda.gov/drugs/drug-safety-and-availability
- **Orange Book**: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

### National Institutes of Health
- **DailyMed Database**: https://dailymed.nlm.nih.gov/
- **PubMed**: https://pubmed.ncbi.nlm.nih.gov/
- **ClinicalTrials.gov**: https://clinicaltrials.gov/

## üîç SEARCH TERMS USED

### Primary Search Terms
- "temozolomide glioblastoma multiforme dosing"
- "bevacizumab avastin recurrent glioblastoma"
- "FDA approved dosing GBM"
- "NCCN guidelines glioblastoma 2024"
- "Stupp protocol temozolomide"

### Database Identifiers
- **Temozolomide CAS**: 85622-93-1
- **Temozolomide NDC**: Various (see DailyMed)
- **Bevacizumab CAS**: 216974-75-3
- **Bevacizumab NDC**: Various (see DailyMed)

---

*This document serves as a comprehensive reference for all source materials used in compiling the GBM clinical data repository. All URLs were accessed in September 2024.*